FPR1 and myeloid sarcoma: In addition, the neutrophils from patients with AQP4+ NMOSD showed an activated phenotype (an increased surface expression of Toll-like receptor 2 and formyl peptide receptor 1) compared with HCs, a compromised functionality (reduced adhesion and migratory capacity as well as decreased reduced production of reactive oxygen species and degranulation) compared with patients with MS [42], and an increased survival capacity in response to phorbol 12-myristate 13-acetate compared with HCs [43].